Tandem Diabetes Care (TNDM)
(Delayed Data from NSDQ)
$43.97 USD
+0.74 (1.71%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $43.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Price, Consensus and EPS Surprise
TNDM 43.97 +0.74(1.71%)
Will TNDM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TNDM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TNDM
Here's How Thermo Fisher (TMO) is Placed Ahead of Q2 Earnings
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
TNDM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
Other News for TNDM
Healthcare 2024 Second Half Outlook
Tandem Diabetes Care to Announce Second Quarter 2024 Financial Results on August 1, 2024
What's Driving Tandem Diabetes Care Inc's Surprising 15% Stock Rally?
Buy Rating Affirmed: Tandem Diabetes Care’s Innovative Edge and Strategic Growth Outlook
Tandem Diabetes, DexCom see weakness following ADA conference